Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
Edward P. Havranek, MD, FACC*,
Ignatius Thomas, MD ,
William B. Smith, MD ,
George A. Ponce, MD ,
Martin Bilsker, MD, FACC||,
Mark A. Munger, PharmD¶,
Robert A. Wolf, MD, FACC# for the Irbesartan Heart Failure Group
* Denver Health Medical Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
Slidell Memorial Hospital, Slidell, Louisiana, USA
Louisiana Cardiovascular Research Center, New Orleans, Louisiana, USA
Adult Cardiovascular Disease, Hemet, California, USA
|| University of Miami School of Medicine, Miami, Florida, USA
¶ University of Utah Heart Failure Treatment Program, Salt Lake City, Utah, USA
# Bristol-Myers Squibb, Princeton, New Jersey, USA
View larger version (26K):
[in a new window]
|
Figure 1 Patient disposition. Reasons for discontinuation of study medication are shown.
|
|
View larger version (25K):
[in a new window]
|
Figure 2 Acute hemodynamic effects of irbesartan. The time course of change from baseline value after the first dose of study medication is shown for pulmonary capillary wedge pressure (PCWP, Fig. 2A), mean pulmonary artery pressure (MPAP, Fig. 2B), mean systemic arterial pressure (MSAP, Fig. 2C) and heart rate (HR, Fig. 2D).
|
|
View larger version (15K):
[in a new window]
|
Figure 3 Long-term effects of irbesartan on pulmonary capillary wedge pressure (PWCP). The time course of change from baseline value for PCWP is shown immediately before (Time 0) and for 24 h after the administration of the last dose of study medication at Week 12.
|
|
|
